NEWARK, Del. and HYDERABAD, India, Jan. 26, 2011 /PRNewswire/ —
QPS, LLC, a leading full-service GLP/GCP-compliant contract
research organization providing testing services to support
preclinical and clinical research and development, announced the
acquisition of a majority stake in Bioserve Clinical Research.
Bioserve, a full service phase 1 CRO headquartered in Hyderabad,
India, will be known as QPS-Bioserve India.
QPS is a global CRO supporting drug discovery and development
since 1995. Its five areas of expertise include: Preclinical
DMPK/Tox, Bioanalytical, Translational Medicine, Early Stage
Clinical and Late Stage Clinical Research.
Bioserve is an ISO 9001:2008 certified organization providing
world-class clinical research services to sponsors across the
globe. Its infrastructure includes a 92-bed clinical unit for
conducting phase I studies and a bioanalytical lab equipped with
multiple LC/MS/MS systems for small molecule bioanalysis. Over the
past 6 years, it has conducted over 500 studies, with numerous
product approvals, and has been inspected by the USFDA, UK MHRA,
WHO and Indian DCGI.
“This new partnership further expands QPS’ global range of
linearly integrated services,” said Ben Chien, PhD, Chairman,
President and CEO of QPS. “With access to Bioserve’s additional
resources, our customers will have the heightened benefits of a
third more phase I beds, bringing our total to 400; greater
bioanalytical capacity; and access to another facility, located in
India, with a reputation for outstanding performance and a record
of timely approvals. Furthermore, current customers will be
reassured to learn that Mr. Suneil Reddy will remain as Managing
The company has been growing at a rate of over 50% per year,
with a current team of over 100 employees. Clients include large
Indian as well as Multinational pharmaceutical firms. Bioserve’s
promoters – the founders of Vijaya Diagnostic Centre, one of the